Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008)

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 4, 2009, Pages 414-426

  Rhomberg, Paul R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenems; Meropenem; MYSTIC Program; Resistance

Indexed keywords

BETA LACTAM DERIVATIVE; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; KLEBSIELLA; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; PREVALENCE; THIENAMYCINS; UNITED STATES;

EID: 71549137756     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.08.020     Document Type: Article

References (68)

1. VIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J. Clin. Microbiol. 45 (2007) 614-615
2. Adam H.J., Hoban D.J., Gin A.S., and Zhanel G.G. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34 (2009) 82-85
3. American Thoracic Society, and Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 15 (2005) 388-416
4. Bradford P.A., Urban C., Mariano N., Projan S.J., Rahal J.J., and Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41 (1997) 563-569
5. Bradford P.A., Bratu S., Urban C., Visalli M., Mariano N., Landman D., Rahal J.J., Brooks S., Cebular S., and Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 39 (2004) 55-60
6. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., and Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165 (2005) 1430-1435
7. Cao V.T., Arlet G., Ericsson B.M., Tammelin A., Courvalin P., and Lambert T. Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J. Antimicrob. Chemother. 46 (2000) 895-900
8. CTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb. Drug Resist. 14 (2008) 211-216
9. Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters-third edition, M23-A3 (2008), CLSI, Wayne, PA
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-10th edition, M02-A10 (2009), CLSI, Wayne, PA
11. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8 (2009), CLSI, Wayne, PA
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) (2009), CLSI, Wayne, PA
13. Crandon J.L., Kuti J.L., Jones R.N., and Nicolau D.P. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann. Pharmacother. 43 (2009) 220-227
14. Deshpande L.M., Rhomberg P.R., Sader H.S., and Jones R.N. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 56 (2006) 367-372
15. EARSS. European Antimicrobial Surveillance System. Available at (2007). http://www.rivm.nl/earss/about Accessed October 25, 2007
16. Edwards J.R. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36 Suppl. A (1995) 1-17
17. Felmingham D., White A.R., Jacobs M.R., Appelbaum P.C., Poupard J., Miller L.A., and Gruneberg R.N. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56 Suppl. 2 (2005) ii3-ii21
18. Fridkin S.K., Steward C.D., Edwards J.R., Pryor E.R., McGowan Jr. J.E., Archibald L.K., Gaynes R.P., and Tenover F.C. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin. Infect. Dis. 29 (1999) 245-252
19. Gales A.C., Biedenbach D.J., Winokur P., Hacek D.M., Pfaller M.A., and Jones R.N. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn. Microbiol. Infect. Dis. 39 (2001) 125-127
20. Harding I., and Felmingham D. PROTEKT years 1-3 (1999-2002): study design and methodology. J. Chemother. 16 Suppl. 6 (2004) 9-18
21. Hossain A., Ferraro M.J., Pino R.M., Dew III R.B., Moland E.S., Lockhart T.J., Thomson K.S., Goering R.V., and Hanson N.D. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob. Agents Chemother. 48 (2004) 4438-4440
22. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., and Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control. Hosp. Epidemiol. 30 (2009) 666-671
23. Jones R.N. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diagn. Microbiol. Infect. Dis. 25 (1996) 153-161
24. Jones R.N. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. J. Antimicrob. Chemother. 46 Suppl. T2 (2000) 1-8
25. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24 (2003) 121-134
26. Jones R.N., and Masterton R. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41 (2001) 171-175
27. Jones R.N., and Pfaller M.A. Ciprofloxacin as broad-spectrum empiric therapy-are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?. Diagn. Microbiol. Infect. Dis. 42 (2002) 213-215
28. Jones R.N., Rhomberg P.R., Varnam D.J., and Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. Int. J. Antimicrob. Agents 20 (2002) 426-431
29. Jones R.N., Deshpande L., Fritsche T.R., and Sader H.S. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Diagn. Microbiol. Infect. Dis. 49 (2004) 211-216
30. Jones R.N., Mendes C., Turner P.J., and Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn. Microbiol. Infect. Dis. 53 (2005) 247-256
31. Jones R.N., Kirby J.T., and Rhomberg P.R. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis. 61 (2008) 203-213
32. Kuti J.L., Dandekar P.K., Nightingale C.H., and Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43 (2003) 1116-1123
33. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48 (2004) 2464-2470
34. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., Flores C., and Brooks S. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162 (2002) 1515-1520
35. Li C., Kuti J.L., Nightingale C.H., and Nicolau D.P. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46 (2006) 1171-1178
36. Masterton R.G. Surveillance studies: how can they help the management of infection?. J. Antimicrob. Chemother. 46 Suppl. T2 (2000) 53-58
37. Mathai D., Rhomberg P.R., Biedenbach D.J., and Jones R.N. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn. Microbiol. Infect. Dis. 44 (2002) 367-377
38. Miriagou V., Tzouvelekis L.S., Rossiter S., Tzelepi E., Angulo F.J., and Whichard J.M. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47 (2003) 1297-1300
39. Mutnick A.H., Rhomberg P.R., Sader H.S., and Jones R.N. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J. Antimicrob. Chemother. 53 (2004) 290-296
40. Package Insert. Merrem (2007), AstraZeneca Pharmaceuticals, Wilmington, DE
41. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6 (2000) 460-463
42. Pfaller M.A., and Jones R.N. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn. Microbiol. Infect. Dis. 28 (1997) 157-163
43. Pfaller M.A., and Jones R.N. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). J. Antimicrob. Chemother. 46 Suppl. T2 (2000) 25-37
44. Pfaller M.A., Jones R.N., and Biedenbach D.J. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41 (2001) 177-182
45. Queenan A.M., Torres-Viera C., Gold H.S., Carmeli Y., Eliopoulos G.M., Moellering Jr. R.C., Quinn J.P., Hindler J., Medeiros A.A., and Bush K. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 44 (2000) 3035-3039
46. Rhomberg P.R., and Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the United States component (2005). Diagn. Microbiol. Infect. Dis. 57 (2007) 207-215
47. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). Antibiot. Clin. 7 (2003) 2-7
48. Rhomberg P.R., Jones R.N., and Sader H.S. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int. J. Antimicrob. Agents 23 (2004) 52-59
49. Rhomberg P.R., Jones R.N., Sader H.S., and Fritsche T.R. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn. Microbiol. Infect. Dis. 49 (2004) 273-281
50. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 17 (2005) 459-469
51. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn. Microbiol. Infect. Dis. 56 (2006) 57-62
52. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States. Diagn. Microbiol. Infect. Dis. 54 (2006) 249-257
53. Rhomberg P.R., Deshpande L.M., Kirby J.T., and Jones R.N. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn. Microbiol. Infect. Dis. 59 (2007) 425-432
54. Roberts J.A., Kirkpatrick C.M., Roberts M.S., Robertson T.A., Dalley A.J., and Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 64 (2009) 142-150
55. Senda K., Arakawa Y., Ichiyama S., Nakashima K., Ito H., Ohsuka S., Shimokata K., Kato N., and Ohta M. PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J. Clin. Microbiol. 34 (1996) 2909-2913
56. Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., and Ohta M. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob. Agents Chemother. 40 (1996) 349-353
57. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., Bartlett J.G., and Edwards Jr. J. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008) 155-164
58. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., and Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 (1995) 2233-2239
59. Toleman M.A., Rolston K., Jones R.N., and Walsh T.R. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48 (2004) 329-332
60. Turner P.J. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J Antimicrob Chemother 46 Suppl. T2 (2000) 9-23
61. Turner P.J. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn. Microbiol. Infect. Dis. 50 (2004) 291-293
62. Turner P.J. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. Diagn. Microbiol. Infect. Dis. 53 (2005) 273-279
63. Turner P.J. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis. 63 (2009) 217-222
64. Turner P.J., Greenhalgh J.M., Edwards J.R., and McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme. Int. J. Antimicrob. Agents 13 (1999) 117-125
65. Wisemann L.R., Wagstaff A.J., Brogden R.N., and Bryson H.M. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50 (1995) 73-101
66. Woodford N., Tierno Jr. P.M., Young K., Tysall L., Palepou M.F., Ward E., Painter R.E., Suber D.F., Shungu D., Silver L.L., Inglima K., Kornblum J., and Livermore D.M. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48 (2004) 4793-4799
67. Woodford N., Hill R.L., and Livermore D.M. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J. Antimicrob. Chemother. 59 (2007) 582-583
68. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., Alberti S., Bush K., and Tenover F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45 (2001) 1151-1161